Core Viewpoint - The company has partially completed the subscription agreement B on December 7, 2025, issuing 1.0037 million new shares at HKD 12.00 per share to subscriber B, while agreeing to terminate the remaining subscription of 2.1513 million shares without any significant adverse impact on its business, operations, or financial condition [1] Group 1 - The company and subscriber B mutually agreed to terminate the remaining subscription of 2.1513 million shares on December 7, 2025, resulting in the expiration of all rights and obligations under subscription agreement B [1] - The board believes that the termination of the remaining shares will not have any significant adverse impact on the company's existing business, operations, or financial condition [1] Group 2 - Subscriber C failed to fulfill its obligations under subscription agreement C by December 7, 2025, leading the company to terminate this agreement as well [1] - Similar to agreement B, the termination of agreement C will not have any significant adverse impact on the company's existing business, operations, or financial condition [1]
圣诺医药-B(02257)：部分完成根据一般授权认购新股份及终止认购协议